---
title: "VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289373738.md"
description: "VERAXA Biotech AG successfully completed its business combination with Voyager Acquisition Corp., debuting on the Nasdaq Capital Market under ticker 'VRXA' on June 11, 2026. The company, focused on next-generation cancer therapies using its BiTAC platform, secured $77.5 million in financing to advance its pipeline of bispecific T-cell engagers and antibody-drug conjugates."
datetime: "2026-06-10T20:15:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289373738.md)
  - [en](https://longbridge.com/en/news/289373738.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289373738.md)
generator: "portal-rs"
---

# VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026

The merger between VERAXA Biotech and Voyager Acquisition Corp. has been finalized, with the stock of the newly formed entity, $VRXA, set to start trading on NASDAQ from June 11, 2026.

### Related Stocks

- [VACH.US](https://longbridge.com/en/quote/VACH.US.md)
- [VACHU.US](https://longbridge.com/en/quote/VACHU.US.md)
- [VACHW.US](https://longbridge.com/en/quote/VACHW.US.md)

## Related News & Research

- [Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference | ANIX Stock News](https://longbridge.com/en/news/296231345.md)
- [05:28 ETChina's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?](https://longbridge.com/en/news/296596921.md)
- [Why Iovance Biotherapeutics Stock Hit 52-Week High](https://longbridge.com/en/news/296522969.md)
- [Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy](https://longbridge.com/en/news/296250397.md)
- [iSpecimen ships hundreds of cancer blood specimens for international research order within three weeks](https://longbridge.com/en/news/296531044.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**